Discover open access scientific publications

Search, annotate, share and cite publications

Publications by Primo N. Lara

Histology-Related Associations of ERCC1, RRM1, and TS Biomarkers in Patients With Non–Small-Cell Lung Cancer: Implications for Therapy

Journal of Thoracic Oncology

English

Diverse EGFR Exon 20 Insertions and Co-Occurring Molecular Alterations Identified by Comprehensive Genomic Profiling of Non-Small Cell Lung Cancer

Journal of Thoracic Oncology

English

NCI 8628: A Randomized Phase 2 Study of Ziv-Aflibercept and High-Dose Interleukin 2 or High-Dose Interleukin 2 Alone for Inoperable Stage III or IV Melanoma

English

Whole Genome and Transcriptional Analysis of Treatment-Emergent Small Cell Neuroendocrine Prostate Cancer Demonstrates Intra-Class Heterogeneity

Molecular Cancer Research

English

Clinical Predictors of Survival in Young Patients With Small Cell Lung Cancer: Results From the California Cancer Registry

English

Evolution and Increasing Complexity of the Therapeutic Landscape in Advanced Non–Small-Cell Lung Cancer

English

Effects of AKT Inhibition on HGF-mediated Erlotinib Resistance in Non-Small Cell Lung Cancer Cell Lines

Journal of Cancer Research and Clinical Oncology

English

Phase II Study of Aflibercept (VEGF-Trap) in Patients With Recurrent or Metastatic Urothelial Cancer, a California Cancer Consortium Trial

Urology

2010

English

Phase II Clinical Trial of the Epothilone B Analog, Ixabepilone, in Patients With Non–Small-Cell Lung Cancer Whose Tumors Have Failed First-Line Platinum-Based Chemotherapy

Journal of Clinical Oncology

English

Bortezomib Plus Gemcitabine/Carboplatin as First-Line Treatment of Advanced Non-Small Cell Lung Cancer: A Phase II Southwest Oncology Group Study (S0339)

Journal of Thoracic Oncology

English

Amanote Research

Discover open access scientific publications

Search, annotate, share and cite publications

Publications by Primo N. Lara

Histology-Related Associations of ERCC1, RRM1, and TS Biomarkers in Patients With Non–Small-Cell Lung Cancer: Implications for Therapy

Diverse EGFR Exon 20 Insertions and Co-Occurring Molecular Alterations Identified by Comprehensive Genomic Profiling of Non-Small Cell Lung Cancer

NCI 8628: A Randomized Phase 2 Study of Ziv-Aflibercept and High-Dose Interleukin 2 or High-Dose Interleukin 2 Alone for Inoperable Stage III or IV Melanoma

Whole Genome and Transcriptional Analysis of Treatment-Emergent Small Cell Neuroendocrine Prostate Cancer Demonstrates Intra-Class Heterogeneity

Clinical Predictors of Survival in Young Patients With Small Cell Lung Cancer: Results From the California Cancer Registry

Evolution and Increasing Complexity of the Therapeutic Landscape in Advanced Non–Small-Cell Lung Cancer

Effects of AKT Inhibition on HGF-mediated Erlotinib Resistance in Non-Small Cell Lung Cancer Cell Lines

Phase II Study of Aflibercept (VEGF-Trap) in Patients With Recurrent or Metastatic Urothelial Cancer, a California Cancer Consortium Trial

Phase II Clinical Trial of the Epothilone B Analog, Ixabepilone, in Patients With Non–Small-Cell Lung Cancer Whose Tumors Have Failed First-Line Platinum-Based Chemotherapy

Bortezomib Plus Gemcitabine/Carboplatin as First-Line Treatment of Advanced Non-Small Cell Lung Cancer: A Phase II Southwest Oncology Group Study (S0339)